More Island Pharmaceuticals Ltd news
Island Pharmaceuticals LtdASX: ILA

Quarterly Activities & Cashflow Report

Apr 29, 2025 at 10:52 PM EDT · Issued by Island Pharmaceuticals Ltd

Filed with ASX · Apr 29, 2025 at 10:52 PM EDT

On 6ix: 6ix.com/news/quarterly-activities-and-cashflow-report-37

Island Pharmaceuticals Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Island Pharmaceuticals Ltd on 6ix

Earlier from Island Pharmaceuticals

  • Phase 2a/b clinical trial updateApr 22, 2025
  • Completion of patient dosing in Phase 2b clinical trialFeb 11, 2025
  • Completion of enrolment in Phase 2b armJan 21, 2025
  • ISLA-101 Phase 2b clinical trial enrols first subjectsJan 7, 2025
  • US patent granted for ISLA-101Dec 10, 2024

Later from Island Pharmaceuticals

  • Island completes $3.6 million placementMay 20, 2025
  • Successful Phase 2 clinical trial of ISLA-101Jun 12, 2025
  • Portfolio expansion achieved with acquisition of GalidesivirJul 8, 2025
  • Completion of Galidesivir transactionJul 30, 2025
  • Options exercise from existing substantial shareholderAug 11, 2025
All Island Pharmaceuticals news releases↗

Follow Island Pharmaceuticals into a list and get an email when it puts out news.

Follow Island Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer